2025-08-07T13:38:46-05:00 2024-09-30 331374517 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2023-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH FOUN 2128061600 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 SHAWN DAVIDSON CFO & COO 2128061600 2025-08-07 1 1 MELISSA MODELSON P01603524 9143818900 2025-08-06 2023 2025-03-06 01:10:19Z AIDS RESEARCH FOUNDATION AMFAR KEVIN FROST 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 49183846 0 X WWW.AMFAR.ORG X 1983 NY AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O) 15 15 75 14 0 0 42216134 39707167 0 0 906419 628771 -14039846 -15490142 29082707 24845796 5747152 4204529 0 0 11557110 11595593 525768 546678 6158125 16110216 13218711 33940246 29565511 -4857539 -4719715 50719163 53354032 18349538 19540426 32369625 33813606 X SEE SCHEDULE O 0 0 9323162 1829960 AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND, BUT UNTESTED HYPOTHESES IN MANY AREAS OF RESEARCH ON HIV/AIDS, WITH A PRIMARY FOCUS ON CURING HIV INFECTION. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES SCIENTISTS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES, WHICH CAN SUBSEQUENTLY BE VALIDATED THROUGH LARGE-SCALE STUDIES. GRANTS AWARDED IN 2024 FOCUSED ON A RANGE OF STRATEGIES AIMED AT ACHIEVING A PRACTICAL, ACCESSIBLE, AND AFFORDABLE CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEULE O. 5422788 2374568 TREAT ASIAFOR NEARLY 25 YEARS, AMFAR'S TREAT ASIA PROGRAM (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) HAS BEEN WORKING WITH PARTNERS ACROSS THE ASIA-PACIFIC REGION TO EXPAND ACCESS TO TREATMENT FOR HIV AND RELATED CONDITIONS SUCH AS HEPATITIS C (HCV) AND IMPROVE STANDARDS OF CARE. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 18 PEDIATRIC SITES IN 12 COUNTRIES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. TREAT ASIA SCIENTISTS PUBLISHED 22 PAPERS IN PEER-REVIEWED MEDICAL JOURNALS IN FY2024. TREAT ASIA AND NETWORK PARTNER RESEARCHTREAT ASIA AND ITS NETWORK PARTNERS CONDUCTED A RANGE OF STUDIES IN 2024, INCLUDING RESEARCH ON LONG-TERM TREATMENT OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV; PREGNANCY OUTCOMES AMONG WOMEN LIVING WITH HIV; LUNG CANCER AND OTHER LUNG CONDITIONS IN HIV AND TB; MENTAL HEALTH; THE BENEFITS OF A RAPID HEPATITIS B VACCINATION REGIMEN FOR VULNERABLE POPULATIONS; COGNITIVE IMPAIRMENT; HPV AMONG ADOLESCENTS; CERVICAL DYSPLASIA AND HPV INFECTION IN WOMEN LIVING WITH HIV; AND PREP UPTAKE. DRAWING ON THE EXPERTISE OF DR. JEREMY ROSS, TREAT ASIA'S DIRECTOR OF RESEARCH, AND NETWORK PARTNERS, TREAT ASIA CONVENED ITS FIRST-EVER THINK TANK ADDRESSING CLINICAL, RESEARCH, AND POLICY NEEDS RELATED TO WOMEN AND HIV IN THE ASIA-PACIFIC REGION WITH THE GOAL OF INFORMING TREAT ASIA'S RESEARCH PLANS FOR THIS VULNERABLE AND OFTEN NEGLECTED POPULATION. INTERNATIONAL AIDS DATABASETREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IEDEA IS CENTRAL TO A WIDE RANGE OF INTERNATIONAL STUDIES IN WHICH TREAT ASIA PARTICIPATES.IEDEA DOLUTEGRAVIR RESISTANCE STUDYTHIS GLOBAL STUDY LED BY THE UNIVERSITY OF BERN AIMS TO IDENTIFY PATTERNS AND RISK FACTORS FOR VIROLOGIC FAILURE IN ADULTS ON DOLUTEGRAVIR-BASED ART, AND TO INVESTIGATE CORRELATIONS BETWEEN RESISTANCE GENOTYPES ACROSS HIV-1 SUBTYPES. THE STUDY IS ONGOING IN THREE IEDEA ASIA-PACIFIC NETWORK SITES IN CAMBODIA (1) AND THAILAND (2). IEDEA TUBERCULOSIS SENTINEL RESEARCH NETWORK: THE STUDY AIMS TO DESCRIBE CLINICAL AND TREATMENT OUTCOMES OF PULMONARY TB AND PROVIDE A PLATFORM FOR GLOBAL TB RESEARCH AMONG PEOPLE WITH AND WITHOUT HIV. THREE SITES IN CAMBODIA AND THAILAND ARE PARTICIPATING.IEDEA SENTINEL RESEARCH NETWORK: THIS GLOBAL STUDY IS ASSESSING LIVER, CARDIO-METABOLIC, MENTAL HEALTH, AND SUBSTANCE USE COMORBIDITIES AMONG PEOPLE WITH HIV OVER 40 YEARS OF AGE, ON ART FOR MORE THAN SIX MONTHS. IT IS BEING IMPLEMENTED AT TWO SITES IN INDIA AND VIETNAM.INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCHTHE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG OF COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE CLINICAL CARE.CHIMERA CREATES THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND BUILDS ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. FELLOWS PRESENTED POSTER ABSTRACTS AT THE HIV AND AGING CONFERENCE IN WASHINGTON, D.C., IN OCTOBER 2023, GAVE ORAL PRESENTATIONS AT THE GLOBAL IEDEA MEETING IN CTE D'IVOIRE IN APRIL, AND PARTICIPATED IN THE ASIA-PACIFIC AIDS & CO-INFECTIONS CONFERENCE IN SINGAPORE IN JUNE. THROUGHOUT THE YEAR, THEY MADE STRIDES IN DATA COLLECTION, DATA CODING, AND PRELIMINARY ANALYSIS. IMPROVING HEALTH THROUGH INFORMATIONOBSERVATIONAL DATABASESTHE INFORMATION GATHERED FROM CLINICAL SITES IN THREE DATABASESTREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD); TAHOD LOW-INTENSITY TRANSFER; AND TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASECONTINUES TO INFORM THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELP DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA.LAUNCHED IN 2021, THE REGION'S FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDSTAHODTRANSITIONED TO THE TAHOD CONTINUUM OF CARE (TAHOD-CC) COHORT IN 2022. IN FY2024, TAHOD-CC CONTINUED ITS DATA COLLECTION AND CLEANING OF TRANSFERS FROM SEPTEMBER 2023, INCLUDING OVER 65,000 PATIENTS FROM 19 ASIA-PACIFIC SITES. THE SEPTEMBER 2024 TRANSFER INCLUDED A NEWLY ADDED SITE, HASAN SADIKIN HOSPITAL/ UNIVERSITAS PADJADJARAN IN BANDUNG, INDONESIA. COMMUNITY-LED MONITORING DASHBOARDWITH THE HELP OF AMFAR'S PUBLIC POLICY OFFICE AND ALONG WITH COMMUNITY NETWORK FOR EMPOWERMENT (CONE) IN MANIPUR, INDIA, AND PEDULI HATI IN INDONESIA, TREAT ASIA DEVELOPED AN ONLINE DASHBOARD (WWW.CLM-ASIA.ORG) TO EXPAND AND ENHANCE COMMUNITY-LED MONITORING IN THE IMPLEMENTING ORGANIZATIONS' RESPECTIVE COUNTRY REGIONS. THE DASHBOARD IS SUPPORTED IN PART BY VIIV HEALTHCARE.TREAT ASIA'S COMMUNITY-LED MONITORING IN ASIA PROJECT IS ALREADY HAVING A SIGNIFICANT IMPACT AT THE COUNTRYWIDE LEVEL. FOR ITS IMPLEMENTATION GUIDELINES, THE INDONESIAN MINISTRY OF HEALTH ADOPTED PROGRAM INDICATORS MEASURING HEPATITIS B AND C CARE DELIVERY DEVELOPED THROUGH THE CLM PROJECT. INTERNATIONAL AIDS CONFERENCE ON HIV SCIENCE AND OTHER CONFERENCESTREAT ASIA HAD A STRONG PRESENCE AT THE 25TH INTERNATIONAL AIDS CONFERENCE. DIRECTOR DR. ANNETTE SOHN GAVE MULTIPLE PRESENTATIONS, INCLUDING ONE AT THE INTERNATIONAL WORKSHOP ON HIV & PEDIATRICS PRECEDING THE MAIN CONFERENCE. GITEN KHWAIRAKPAM, TREAT ASIA'S PROGRAM MANAGER, COMMUNITY AND POLICY, AND NUMEROUS TREAT ASIA PARTNER INVESTIGATORS AND AFFILIATES ALSO PRESENTED AT THE CONFERENCE.IN ADDITION TREAT ASIA PARTICIPATED IN THE SINGAPORE HIV CONGRESS 2023; AND, IN 2024, THE 26TH BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE; THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS AND THE GLOBAL IEDEA MEETING, BOTH IN DENVER, COLORADO; THE 26TH INTERNATIONAL WORKSHOP ON HIV AND HEPATITIS OBSERVATIONAL DATABASES IN VILAMOURA, PORTUGAL; THE ALL IEDEA GLOBAL MEETING, IN ABIDJAN, CTE D'IVOIRE; APACC 2024 IN HONG KONG; THE FOGARTY INTERNATIONAL CENTER (FIC) HIV RESEARCH TRAINING NETWORK MEETING (VIRTUAL); AND THE 10TH GLOBAL VALIDATION ADVISORY COMMITTEE MEETING FOR ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION OF HIV, SYPHILIS, AND HEPATITIS B VIRUS IN GENEVA, SWITZERLAND.PUBLICATIONSALONG WITH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC REGION, TREAT ASIA PUBLISHED A FACT SHEET TITLED UNDERSTANDING WHO GUIDELINES FOR THE PREVENTION, CARE, DIAGNOSIS, AND TREATMENT OF PEOPLE WITH CHRONIC HEPATITIS B INFECTION. 3747325 PUBLIC INFORMATIONAMFAR TRANSLATES AND DISSEMINATES INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION AND TREATMENT, AND A CURE FOR HIV. EDUCATIONAL MATERIALS AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND DIGITAL FORMATS, INCLUDING ITS NEWSLETTER, INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO ABOUT 16,000 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER, INSIGHTS, DISTRIBUTED TO APPROXIMATELY 20,000 RECIPIENTS. THE FOUNDATION'S WEBSITEWWW.AMFAR.ORGFEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITE ATTRACTS AN AVERAGE OF 36,500 MONTHLY VISITS. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE AND TREAT ASIA STAFF (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.SOCIAL MEDIAAMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. POSTS IN FY2024 COVERED TOPICS SUCH AS HIV FUNDING PRIORITIES IN THE AMERICAN SOUTH, HIV CRIMINALIZATION, CUTS IN HIV FUNDING, PREP ACCESS, AND THE IMPORTANCE OF REAUTHORIZING PEPFAR. AMFAR REGULARLY UPDATES ITS SOCIAL CHANNELS WITH THE LATEST RESEARCH BREAKTHROUGHS AND POLICY NEWS, AS WELL AS DETAILED COVERAGE FROM ITS WORLD-RENOWNED FUNDRAISING GALAS. ATTUNED TO THE SHIFTING LANDSCAPE OF SOCIAL MEDIA, AMFAR HAS EXPANDED ITS SOCIAL MEDIA PRESENCE TO INCLUDE THREADS AND BLUESKY, AND INCREASED MESSAGING ON LINKEDIN. AMFAR HAS 84,000 FOLLOWERS ON FACEBOOK, MORE THAN 41,000 X (FORMERLY TWITTER) FOLLOWERS, OVER 121,000 TIKTOK FOLLOWERS, 36,200 THREADS FOLLOWERS, AND 206,000 INSTAGRAM FOLLOWERS. IN RESPONSE TO AMFAR GALA CANNES, THE FOUNDATION GARNERED OVER 3.3 MILLION VIDEO VIEWS WITH 6.5 MILLION IMPRESSIONS ON OWNED SOCIAL CHANNELS AND 46,000 TOTAL MENTIONS OF AMFAR ONLINE, AND GAINED 10,350 FOLLOWERS ACROSS CHANNELS. MEDIA OUTREACHAMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. AMFAR GARNERED APPROXIMATELY 5,430 MENTIONS ACROSS MEDIA IN FY2024. ARTICLES AND REPORTS INVOLVING AMFARMANY OF WHICH INCLUDED INTERVIEWS WITH STAFFWERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING THE NEW YORK TIMES, THE WASHINGTON POST, JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, THE LANCET, THE GUARDIAN, BILLBOARD, THE HILL, MEDSCAPE, POZ, POSITIVELY AWARE, PARIS MATCH, PEOPLE, POLITICO, VANITY FAIR, VARIETY, VOGUE, WOMEN'S WEAR DAILY, ELLE, ESQUIRE, THE HOLLYWOOD REPORTER, TOWN & COUNTRY, REUTERS, AP NEWS, YAHOO, CBS NEWS, AND ABC NEWS.MULTIMODAL AWARENESS-RAISINGAMFAR FREQUENTLY SPOTLIGHTS AIDS AWARENESS NOT ONLY ACROSS DIFFERENT PLATFORMS BUT ACROSS DIFFERENT MEDIA IN ORDER TO REACH DIVERSE AUDIENCES. FOR WORLD AIDS DAY ON DECEMBER 1, 2023, AMFAR'S PUBLIC INFORMATION TEAM PRODUCED A VIDEO FEATURING THE ORGANIZATION'S CEO, PROGRAM HEADS, BOARD CO-CHAIRS, AND CELEBRITY SUPPORTERS, OFFERING INSIGHTS INTO PROGRESS ON HIV/AIDS, DOMESTIC AND FOREIGN HIV POLICY, AND CURRENT HIV RESEARCH. AMFAR MARKED NATIONAL HIV/AIDS AWARENESS DAYS THROUGHOUT THE YEAR.IN DECEMBER 2023, AMFAR COMMISSIONED A HARRIS POLL THAT ASKED A SAMPLE OF 2,053 ADULTS IN THE U.S. ABOUT THEIR KNOWLEDGE OF AND ATTITUDES TOWARD HIV AS A PUBLIC HEALTH THREAT, HIV TREATMENT AND PREVENTION, AND HIV CURE RESEARCH. THE RESULTS WERE SHARED WIDELY IN PRINT AND ONLINE.FOR THE 2024 INTERNATIONAL AIDS CONFERENCE IN MUNICH, GERMANY, AMFAR CREATED A WEB PLATFORM PROMOTING AMFAR STAFF PRESENTATIONS AND WORKSHOPS AND PROVIDING DAILY IN-PERSON REPORTING. AND IN JUNE 2024, AMFAR EXHIBITED AT THE 28TH ANNUAL BROOKLYN PRIDE MULTICULTURAL FESTIVAL IN BROOKLYN, NEW YORK, TO HELP RAISE AWARENESS ABOUT HIV/AIDS AND THE VITAL WORK THE ORGANIZATION DOES.CELEBRITY SUPPORT AMFAR'S PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATION'S MISSION. SUPPORT OF AMFAR FROM PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFAR'S FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD.CELEBRITY SUPPORTERS INCLUDED PEDRO ALMODVAR, JONATHAN BAILEY, ANTONIO BANDERAS, ANGELA BASSETT, KATE BECKINSALE, CHER, ALAN CUMMING, WILLEM DAFOE, JASON DERULO, COLMAN DOMINGO, CYNTHIA ERIVO, RICHARD GERE, GOLDIE HAWN, TOMMY HILFIGER, KRIS JENNER, NICK JONAS, MILLA JOVOVICH, HEIDI KLUM, DIANE KRUGER, JULIAN LENNON, EVA LONGORIA, ANDIE MACDOWELL, JULIANNA MARGULIES, DEMI MOORE, CATHERINE O'HARA, VANESSA REDGRAVE, JOELY RICHARDSON, AMBER RILEY, COCO ROCHA, MICHELLE RODRIGUEZ, CARINE ROITFELD, KELLY ROWLAND, ALEXANDER SKARSGRD, STING, SYLVESTER STALLONE, ELLEN VON UNWERTH, DIONNE WARWICK, RUMER WILLIS, JEFFREY WRIGHT, MICHELLE YEOH, AND ZHANG ZIYI. 2123875 PUBLIC POLICY ENDING THE HIV EPIDEMIC IN THE U.S.THROUGHOUT THE YEAR, AMFAR WORKED CLOSELY WITH MEMBERS OF THE BIDEN ADMINISTRATION, THE CDC, NATIONAL INSTITUTES OF HEALTH, AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. AMFAR FOCUSED MUCH OF ITS EFFORTS ON KEEPING DOMESTIC AND INTERNATIONAL HIV FUNDING ON TRACK AND CONTINUING ITS DATA-DRIVEN ADVOCACY OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY, WHILE ENGAGING IN EFFORTS TO EXPAND ACCESS TO PREVENTION, TREATMENT, AND CARE FOR MARGINALIZED POPULATIONS; PROMOTE WOMEN'S HEALTH RESEARCH; INCORPORATE TECHNOLOGY INTO HEALTHCARE DELIVERY, POLICY, RESEARCH, AND EDUCATION; AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. AT CROI 2024, STAFF PRESENTED AN ABSTRACT ON THE NEGATIVE IMPACT OF TITLE X FAMILY PLANNING PROGRAM FUNDING RESTRICTIONS ON HIV TESTING AND DIAGNOSES. THE STUDY FOUND AN OVERALL DECLINE IN REGIONAL HIV TESTING FROM BEFORE AND AFTER THE FEDERAL REGULATION WAS INSTITUTED, LIKELY RELATED TO BOTH THE NEW RESTRICTIONS AND COVID-19. HOWEVER, THE DECLINE IN OVERALL REGIONAL HIV TESTING WAS SIGNIFICANTLY GREATER IN REGIONS HIGHLY IMPACTED BY THE FEDERAL REGULATION, SUPPORTING THE THEORY THAT THE FEDERAL REGULATION DROVE THE REDUCTION IN REGIONAL HIV TESTING AT TITLE X SITES BEYOND TRENDS RELATED TO COVID-19.ENSURING GLOBAL HEALTH ACCESSAMFAR MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES, AND POLICY STAFF PARTICIPATE IN PEPFAR COUNTRY OPERATIONAL PLAN MEETINGS, THE GLOBAL FUND PARTNERSHIP FORUM, AND THE UN HIGH-LEVEL MEETINGS ON HIV/AIDS. AMFAR ENGAGES IN ADVOCACY WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES TO SECURE STRONG GLOBAL HIV BUDGETS AND CLOSELY TRACK AND RESPOND TO NEW GLOBAL HEALTH POLICIES. IN 2024, AMFAR PARTICIPATED IN A PEPFAR FIVE-YEAR STRATEGY MEETING, PROVIDED INPUT INTO THE DEVELOPMENT AND IMPLEMENTATION OF THE PEPFAR MID-TERM REVIEW PROCESS, AND HELD SEVERAL MEETINGS WITH PEPFAR STAFF. AMFAR ALSO MET WITH WHO, THE GLOBAL FUND, UNAIDS, AND OTHERS TO DISCUSS THE HIV IMPLICATIONS OF THE GLOBAL GAG RULE.ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN TEN COUNTRIESSOUTH AFRICA, LESOTHO, MALAWI, UGANDA, KENYA, TANZANIA, HAITI, ZIMBABWE, AND (WITH TREAT ASIA) INDIA AND INDONESIA. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY INITIATIVES. AMFAR PARTICIPATED IN NUMEROUS PRESENTATIONS AND PANELS AT MEETINGS AND CONFERENCES THROUGHOUT THE YEAR. STAFF DELIVERED PRESENTATIONS AT THE INTERNATIONAL CONFERENCE ON AIDS AND STIS IN AFRICA IN HARARE, ZIMBABWE, IN DECEMBER 2023. AT THE 25TH INTERNATIONAL AIDS CONFERENCE, AMFAR SUBMITTED SEVEN ABSTRACTS COVERING TOPICS SUCH AS HIV-FOCUSED IMPLEMENTATION SCIENCE AND COMMUNITY-LED MONITORING. AMFAR PUBLISHED A NEW POLICY BRIEF, DUAL EPIDEMICS: LEVERAGING HIV INFRASTRUCTURE TO SUPPORT HPV PREVENTION, TESTING, AND CERVICAL CANCER ELIMINATION GOALS, THAT EXAMINES HOW HIV AND HPV INTERSECT AND NEGATIVELY IMPACT WOMEN'S HEALTH OUTCOMES, AND HOW SERVICE DELIVERY FOR BOTH COULD BE INTEGRATED. THE BRIEF DESCRIBES DIFFERENT SERVICE INTEGRATION MODELS THAT RANGE FROM TRAINING EXISTING CLINIC STAFF TO ENGAGING BROAD REFERRAL NETWORKS, ALL OF WHICH ARE TAILORED TO THE UNIQUE NEEDS OF WOMEN LIVING WITH HIV. IT ALSO OFFERS CONCRETE RECOMMENDATIONS TO EXPAND PRIMARY PREVENTION WITH ART COVERAGE AND HPV VACCINATION, INCREASE ACCESS TO CERVICAL CANCER SCREENING AND TREATMENT TOOLS, ENHANCE DATA AVAILABILITY, BUILD MULTI-SECTORAL PARTNERSHIPS, AND MAXIMIZE TECHNOLOGICAL INNOVATIONS.IN ADDITION, AMFAR'S POLICY TEAM CO-HOSTED A WEBINAR, ADVANCING GLOBAL HEALTH EQUITY: INVESTING IN INTEGRATED HIV, HPV, AND CERVICAL CANCER INITIATIVES, WITH FUNDERS CONCERNED ABOUT AIDS TO EDUCATE HIV DONORS ON OPPORTUNITIES TO INTEGRATE PROGRAMS ON THESE DISEASES.EMPOWERMENT THROUGH DATAAMFAR IS AT THE FOREFRONT OF DATA COLLECTION FOR ADVOCACY PURPOSES, FORTIFYING PUBLIC HEALTH RESPONSES WITH ACCURATE INFORMATION. IN FY2024, FOR EXAMPLE, AMFAR MET WITH CDC STAFF TO INCORPORATE THE AGENCY'S DATA INTO ADDITIONAL HIV-RELATED POLICY ANALYSES.IN ADDITION, AMFAR MAINTAINS A SUITE OF FREE INTERACTIVE DATABASES THAT ARE INVALUABLE RESOURCES FOR INDIVIDUALS AND ORGANIZATIONS WORKING TO SECURE AND MONITOR HIV-RELATED FUNDING AND TAILOR PROGRAMS TO MEET THE NEEDS OF CLIENTS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS DATA AND PREPARE ADVOCACY INITIATIVES. THE FIVE DATABASES ARE: PEPFAR MONITORING, EVALUATION, AND REPORTING (MER.AMFAR.ORG) PEPFAR COUNTRY/REGIONAL OPERATIONAL PLANS (COPSDATA.AMFAR.ORG) KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) ENDING THE HIV EPIDEMIC IN THE U.S. (EHE.AMFAR.ORG) OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) SHARING KNOWLEDGE, AMPLIFYING EXPERTISEIN APRIL 2024, AMFAR AND PARTNER ORGANIZATIONS RELEASED A REPORT TITLED COMMUNITY ENGAGEMENT IN GLOBAL FUND COUNTRY COORDINATING MECHANISMS: FINDINGS FROM THE RISE STUDY. THE RISE (REPRESENTATION, INCLUSION, SUSTAINABILITY, AND EQUITY) STUDY IS AN INDEPENDENT, COMMUNITY-OWNED RESEARCH PROJECT CO-SPONSORED BY AMFAR THAT EXAMINES THE GRANTMAKING PROCESSES OF THE GLOBAL FUND TO FIGHT TB, MALARIA AND AIDS. STUDY AUTHORS CONDUCTED A SURVEY AS WELL AS IN-DEPTH INDIVIDUAL INTERVIEWS WITH OVER 650 ELIGIBLE PARTICIPANTS FROM 83 COUNTRIES. THE RISE STUDY WAS HONORED WITH THE PRESTIGIOUS 2024 ROBERT CARR RESEARCH AWARD AT THE 2024 INTERNATIONAL AIDS CONFERENCE.THROUGHOUT THE YEAR, AMFAR STAFF PUBLISHED ARTICLES ON A RANGE OF TOPICS IN ACADEMIC AND POLICY JOURNALS: THE LANCET HIV, OCTOBER 2024, "THE LONG WAIT FOR LONG-ACTING HIV PREVENTION AND TREATMENT FORMULATIONS" THE LANCET HIV, JULY 2024, "IS HIV EPIDEMIC CONTROL BY 2030 REALISTIC?" PLOS GLOBAL PUBLIC HEALTH, JUNE 2024, "FACILITATORS AND BARRIERS TO COMMUNITY-LED MONITORING OF HEALTH PROGRAMS: QUALITATIVE EVIDENCE FROM THE GLOBAL IMPLEMENTATION LANDSCAPE" THE HILL, JUNE 2024, "AIDS AMNESIA IS PUTTING WOMEN'S LIVES AT RISK" JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, DECEMBER 2023, "THERE IS NO PATH TO ENDING AIDS BY 2030 WITHOUT IMPROVING HUMAN RIGHTS" 2123875 20617150 1 1 0 1 0 0 0 1 1 1 1 0 0 1 1 1 1 0 0 1 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 119 0 75 1 0 1 TH 0 0 0 1 1 0 0 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OR PA RI SC TN UT VA WI WV X X X SHAWN DAVIDSON 2128061600 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 T RYAN GREENWALT CO-CHAIR 1.00 X X 0 0 0 KEVIN MCCLATCHY CO-CHAIR 1.00 X X 0 0 0 ROBERT L TRAYNHAM II SECRETARY 1.00 X X 0 0 0 DONALD DYE TREASURER 1.00 X 0 0 0 AMY ANDELSON TRUSTEE 1.00 X 0 0 0 GLEN ISAACSON TRUSTEE 1.00 X 0 0 0 MICHAEL LORBER TRUSTEE 1.00 X 0 0 0 ANTHONY MANCILLA TRUSTEE 1.00 X 0 0 0 ARON MARQUEZ TRUSTEE 1.00 X 0 0 0 LARRY MILSTEIN TRUSTEE 1.00 X 0 0 0 CINDY RACHOFSKY TRUSTEE 1.00 X 0 0 0 VINCENT A ROBERTI TRUSTEE 1.00 X 0 0 0 MERV SILVERMAN TRUSTEE 1.00 X 0 0 0 JEFFREY SCHOENFELD TRUSTEE 1.00 X 0 0 0 MARIO STEVENSON TRUSTEE 1.00 X 0 0 0 JAY ELLIS TRUSTEE THRU JUNE 2024 1.00 X 0 0 0 PHILL WILSON TRUSTEE THRU MARCH 2024 1.00 X 0 0 0 KEVIN FROST CHIEF EXECUTIVE OFFICER 40.00 X 646627 0 125342 BRADLEY JENSEN ASSISTANT TREASURER/CFO 40.00 X 296502 0 82342 SEBASTIAN GHEITH GENERAL COUNSEL, ASST SECRETARY 40.00 X 192039 0 93754 RONALD KIRK ASSISTANT TREASURER, CONTROLLER 40.00 X 121084 0 16465 KYLE CLIFFORD VICE PRESIDENT OF DEVELOPMENT 40.00 X 259193 0 80355 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA 40.00 X 285584 0 29913 GREGORIO MILLET VICE PRESIDENT, PUBLIC POLICY 40.00 X 203864 0 76338 JAMES SHAKLEFORD VICE PRESIDENT PUBLIC INFORMATION, THRU AUG. 2024 40.00 X 227281 0 30490 ANTHONY ANCONA VICE PRESIDENT OF HUMAN RESOURCES 40.00 X 213915 0 77150 ANDREW MCINNES DIRECTOR, PUBLICATIONS 40.00 X 192901 0 75386 JOSEPH FERRERA DIRECTOR PHILANTHROPY, THRU NOV. 2023 40.00 X 155240 0 84074 CHRISTOPHER FREDERICK SPECIAL EVENTS DIRECTOR 40.00 X 186606 0 39097 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 40.00 X 149250 0 90679 ROWENA JOHNSTON FORMER ASST SEC, VP, RESEARCH 40.00 X 118492 0 18835 3248578 0 920220 24 1 1 0 RAFANELLI EVENTS MANAGEMENT INC 361 NEWBURY STREET 5TH FL BOSTON MA 02115 EVENT MANAGEMENT 1057785 AAB PRODUCTIONS INC 64 ALLEN ROAD 5TH FLOOR NEW YORK NY 10002 EVENT PRODUCTION 376600 SANKY COMMUNICATIONS INC 360 W 31ST ST FL 6 NEW YORK NY 10001 DIRECT MAIL/RESPONSE CONSULTANTS 350654 TODD EVENT DESIGN 1174 QUAKER STREET DALLAS TX 75207 EVENT PRODUCTION 276893 ART 2 CATERING 2515 E ROSEMEADE PKWY NO 115 CARROLLTON TX 75007 CATERING 240465 17 76663 23826183 8282568 7521753 241641 39707167 1059334 1059334 218807 218807 81000 0 81000 81000 81000 7008421 7438984 -430563 -430563 -430563 1095500 23826183 16898897 -15803397 -15803397 11736 0 11736 11736 1187 169 1018 1018 MISCELLANEOUS INCOME 900099 694 694 694 24845796 1018 0 -14862389 753499 753499 3451030 3451030 2888802 1974722 398831 515249 5755378 3708784 623672 1422922 373945 246223 41815 85907 2034855 1252343 347146 435366 542613 337786 68531 136296 77137 74762 1826 549 143666 143666 100000 100000 546678 546678 188065 188065 1063355 413603 161449 488303 313368 243087 3581 66700 98012 52028 11123 34861 221099 141961 32572 46566 1746754 1106565 263341 376848 1230786 473220 3184 754382 350081 335926 8234 5921 87193 55237 13145 18811 457755 289987 69011 98757 345352 218780 52065 74507 PROGRAM MATERIALS 3830363 3830363 PROGRAM TECHNICAL SUPPO 600712 600712 SUBSCRIPTION & DUES 576504 367683 76726 132095 POSTAGE 491563 294391 1684 195488 1296946 294458 280569 721919 29565511 20617150 2790236 6158125 791311 1914515 635034 1128104 81603 70732 7282525 5146670 95730 92130 1792963 1763416 7811376 5748732 2278757 2062644 33561440 36477231 4199800 4698590 50719163 53354032 6278878 6125286 669464 32446 5040944 6592061 0 18000 1311267 1398459 5048985 5374174 18349538 19540426 X 29879962 31263900 2489663 2549706 32369625 33813606 50719163 53354032 X -4719715 6460619 -296923 X X 0 1 X 1 1 1 X 21625761 28156638 43281833 42216134 39707167 174987533 21625761 28156638 43281833 42216134 39707167 174987533 554740 174432793 1252653 1025000 1328141 1301913 1359141 6266848 3067 7858 18851 115 694 30585 181284966 63989 0.96220 0.96250 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2019 AMOUNT: $ 165. 2020 AMOUNT: $ 6,555. 2022 AMOUNT: $ 115. 2023 AMOUNT: $ 694. LIST RENTALS - 2019 AMOUNT: $ 2,201. STORE SALES - 2019 AMOUNT: $ 701. 2020 AMOUNT: $ 1,303. IRS TAX REFUND - 2021 AMOUNT: $ 18,851. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 244797 244797 0 PART II-B, LINE 1: THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. THE FOUNDATION ENGAGED AN INDEPENDENT CONSULTANT TO ENGAGE IN LOBBYING ACTIVITIES ON ITS BEHALF. FEES PAID TO THIS CONSULTANT TOTALED $100,000 IN THE FISCAL YEAR ENDING SEPTEMBER 30, 2024. 86326 X DONATED ITEMS, INVENTORY ETC. 1 0 1 X 744314 750 84293 829357 702275 6450 35589 744314 785615 4700 -88040 702275 731736 5380 48499 785615 701368 7933 22435 731736 0.00000 0.48800 0.51200 0 0 2573778 2168605 405173 868500 863818 4682 4369098 2716309 1652789 2062644 SECURITY DEPOSITS 58289 RIGHT OF USE ASSETS 4096770 DEBT SERVICE RESERVE 525215 EMPLOYEE ADVANCES 18316 4698590 SEC. 457 RETIREMENT LIABILITY 525215 OPERATING LEASES 4848959 5374174 X 31049519 6460619 12000 169 6472788 24576731 188065 81000 269065 24845796 29605538 12000 297092 309092 29296446 188065 81000 269065 29565511 PART III, LINE 4: AMFAR SOLICITS ARTWORK FOR OUR EVENT AUCTIONS ARTWORK MAY BE DONATED OUTRIGHT, ON CONSIGNMENT OR SOMETIMES AMFAR PURCHASES THE PIECE IF IT CAN BE AUCTIONED WITH A LARGE ENOUGH RETURN. SOME ARE OUTRIGHT DONATIONS TO BE AUCTIONED AND SOME ARE PROVIDED ON CONSIGNMENT FOR THE AUCTION. PART IV, LINE 2B: THE ORGANIZATION HOLDS A SECURITY DEPOSIT FROM A SUBTENANT IN AN ESCROW ACCOUNT. THIS DEPOSITS IS RETURNED ONCE THEY MOVE OUT OF THE SPACE AS PER LEASE TERMS AND RELEVANT LAW. PART V, LINE 4: AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. PART X, LINE 2: AMFAR RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT AMFAR HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. AMFAR IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO 2021. PART XI, LINE 2D - OTHER ADJUSTMENTS: COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 169. PART XI, LINE 4B - OTHER ADJUSTMENTS: RECLASS OF SUBLEASE RENTAL INCOME TO PART VIII, LINE 6A 81,000. PART XII, LINE 2D - OTHER ADJUSTMENTS: COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 169. WRITE OFF OF UNCOLLECTIBLE PLEDGES 499. RECLASS OF OVERACCRUAL OF GRANT EXPENSES 296,424. PART XII, LINE 4B - OTHER ADJUSTMENTS: RECLASS OF SUBLEASE RENTAL INCOME TO PART VIII, LINE 6A 81,000. 0 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING SERVICES THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING 11790377 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 1007824 SOUTH ASIA 0 0 GRANTMAKING 193573 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 2197377 EAST ASIA AND THE PACIFIC 1 15 PROGRAM SERVICES THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING 1660907 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 52256 1 15 0 0 1 15 16902314 0 16902314 EUROPE RESEARCH 674813 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 549859 WIRE TRANSFER 0 EUROPE RESEARCH 258011 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 222322 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 193778 WIRE TRANSFER 0 SOUTH ASIA TREAT ASIA 156625 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC RESEARCH 147418 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 110720 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 103028 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 94075 WIRE TRANSFER 0 EUROPE RESEARCH 75000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 68658 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 68270 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 66273 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 58492 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC RESEARCH 52500 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH 52256 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 43636 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 31671 WIRE TRANSFER 0 SOUTH ASIA TREAT ASIA 29996 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 25649 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 17500 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 17500 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 17500 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 17500 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 16820 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 15000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 15000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 15000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 12000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 11967 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 11622 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10359 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 10343 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 9260 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 9170 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8775 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 8500 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7940 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7620 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE TRANSFER 0 SOUTH ASIA TREAT ASIA 6952 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6921 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6825 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6600 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6541 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6231 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 6150 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC TREAT ASIA 5170 WIRE TRANSFER 0 52 0 0 0 0 0 0 0 PART I, LINE 2: FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE, PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH STEPS REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORT IN ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES - PART I, LINE 3, COLUMN D: THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S CHARITIES. PART I, LINE 3: THE ORGANIZATION USES THE ACCRUAL METHOD TO ACCOUNT FOR EXPENDITURES. X X X X X X 1 AAB PRODUCTIONS 387 GRAND STREET SUITE K705 NEW YORK NY 10002 SPECIAL EVENT PRODUCTION 0 17316503 285298 17031205 SANKY COMMUNICATIONS INC 360 W 31ST STREET FLOOR 6 NEW YORK NY 10001 DIRECT MAIL DIRECT RESPONSE CONSULTING 0 1221208 261380 959828 18537711 546678 17991033 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NH NJ NM NY NC ND OH OK OR PA RI SC SD TN UT VT VA WA WV WI WY CANNES GALA 14273670 13871170 402500 1408892 534677 3012376 5299381 DALLAS TWO BY TWO 4789920 4535420 254500 247652 300758 303187 1177603 3 5858093 5419593 438500 41976 405519 1162173 3004703 24921683 23826183 1095500 1698520 1240954 4477736 9481687 16898897 -15803397 PART I, LINE 2B, COLUMN (V): THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $546,678 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2024. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $729,178 OF THAT $729,178 ONLY $546,678 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $182,500 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE. 1 UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94143 946036493 501(C)(3) 185970 0 RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 501(C)(3) 160410 0 RESEARCH JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21287 520595110 501(C)(3) 142820 0 TREAT ASIA CASE WESTERN RESERVE UNIVERSITY 0900 EUCLID AVENUE LC 4930 CLEVELAND OH 44106 341018992 501(C)(3) 69079 0 RESEARCH WASHINGTON UNIVERSITY SCHOOL OF MEDICINE 4566 SCOTT AVE MDS ONCOLOGY RM 562 ST LOUIS MO 63110 430653611 501(C)(3) 52430 0 RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 946036493 501(C)(3) 40825 0 RESEARCH COLUMBIA UNIVERSITY 630 WEST 168TH ST BOX 49 NEW YORK NY 100323702 135598093 501(C)(3) 40716 0 TREAT ASIA UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY SUITE 650 CORAL GABLES FL 33146 590624458 501(C)(3) 31250 0 RESEARCH COMPASS INC 201 NORTH DIXIE HIGHWAY LAKE WORTH FL 33560 650052657 501(C)(3) 25000 0 RESEARCH 9 0 PART I, LINE 2: AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH SUBAWARD TERMS. X X X X 0 1 0 0 0 0 0 1 0 KEVIN FROST CHIEF EXECUTIVE OFFICER 484713 0 125000 0 36914 0 45600 0 79742 0 771969 0 0 0 BRADLEY JENSEN ASSISTANT TREASURER/CFO 296502 0 0 0 0 0 20715 0 61627 0 378844 0 0 0 KYLE CLIFFORD VICE PRESIDENT OF DEVELOPMENT 259193 0 0 0 0 0 18728 0 61627 0 339548 0 0 0 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA 285584 0 0 0 0 0 19990 0 9923 0 315497 0 0 0 ANTHONY ANCONA VICE PRESIDENT OF HUMAN RESOURCES 213915 0 0 0 0 0 15523 0 61627 0 291065 0 0 0 SEBASTIAN GHEITH GENERAL COUNSEL, ASST SECRETARY 192039 0 0 0 0 0 14012 0 79742 0 285793 0 0 0 GREGORIO MILLET VICE PRESIDENT, PUBLIC POLICY 203864 0 0 0 0 0 14711 0 61627 0 280202 0 0 0 ANDREW MCINNES DIRECTOR, PUBLICATIONS 192901 0 0 0 0 0 13759 0 61627 0 268287 0 0 0 JAMES SHAKLEFORD VICE PRESIDENT PUBLIC INFORMATION, THRU AUG. 2024 227281 0 0 0 0 0 6708 0 23782 0 257771 0 0 0 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 149250 0 0 0 0 0 10937 0 79742 0 239929 0 0 0 JOSEPH FERRERA DIRECTOR PHILANTHROPY, THRU NOV. 2023 155240 0 0 0 0 0 11450 0 72624 0 239314 0 0 0 CHRISTOPHER FREDERICK SPECIAL EVENTS DIRECTOR 186606 0 0 0 0 0 13209 0 25888 0 225703 0 0 0 ROWENA JOHNSTON FORMER ASST SEC, VP, RESEARCH 118492 0 0 0 0 0 8304 0 10531 0 137327 0 0 0 PART I, LINE 4B CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NON-QUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2023, AMFAR CONTRIBUTED $36,914 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTION AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J, COLUMN (B) (III) IS MR. FROST'S 2023 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $36,914. PART I, LINE 7 THE ORGANIZATION PAID BOARD APPROVED DISCRETIONARY BONUSES TO CERTAIN INDIVIDUALS LISTED IN PART II AS REPORTED IN COLUMN B(II) FOR THE APPLICABLE INDIVIDUALS. X 3 81403 AVG. SELLING PRICE X 5 160238 COST 0 0 0 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN PART I, COLUMN (B) OF SCHEDULE M. FORM 990, PART III, LINE 1: THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES FOR PREVENTING, TREATING, AND CURING HIV AND OTHER INFECTIOUS DISEASE THREATS AND ENHANCING THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; AND - PUBLIC INFORMATION PROGRAMS TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PROVIDE UP-TO-DATE MEDICAL, SCIENTIFIC, AND PREVENTION INFORMATION TO PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. FORM 990, PART III, LINE 4A ARCHE GRANTS CONTROLLING HIV TWO ARCHE GRANTS FUNDED STUDIES TO UNDERSTAND AND POTENTIALLY ENHANCE CONTROL OF HIV, EITHER AS A RESULT OF A CURE INTERVENTION OR AS A NATURAL OCCURRENCE. STUDIES HAVE SHOWN THAT FOR SOME INDIVIDUALS WITH ART, ADMINISTERING A COCKTAIL OF BROADLY NEUTRALIZING ANTIBODIES (BNABS) AT THE TIME OF TEMPORARILY STOPPING ARTAS PART OF A CLINICAL CURE STUDYIMPROVES CONTROL OF HIV, THOUGH THE VIRUS EVENTUALLY REAPPEARS DESPITE ABSENCE OF DETECTABLE LEVELS OF ART OR BNABS. DR. RACHEL RUTISHAUSER AND A TEAM OF CO-INVESTIGATORS FROM THE U.S. AND DENMARK, INCLUDING DRS. STEVEN DEEKS AND MICHAEL PELUSO OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH AT UCSF, ARE INVESTIGATING POSSIBLE MECHANISMS THAT MEDIATE THIS CONTROL. DR. XU YU OF MASSACHUSETTS GENERAL HOSPITAL, RECEIVED ADDITIONAL ARCHE FUNDING TO CONTINUE HER STUDY AIMED AT UNDERSTANDING WHY SOME PEOPLE LIVING WITH HIVSUCH AS LOREEN WILLENBERG AND AN ARGENTINIAN WOMAN KNOWN AS THE ESPERANZA PATIENTARE SEEMINGLY ABLE TO CLEAR REPLICATION-COMPETENT HIV WITHOUT THE BENEFIT OF ART OR OTHER MEDICAL INTERVENTIONS. THE ADDITIONAL FUNDING SUPPORTS HIGH-RESOLUTION RESERVOIR EVALUATIONS OF 66 INDIVIDUALS WHO HAVE BEEN ON ART FOR AT LEAST 15 YEARS BUT WHO MAY BE CONTROLLING HIV NATURALLY, AND, MOST IMPORTANTLY, A CLINICAL STUDY TO DETERMINE IF TIME AND IMMUNITY HAVE LED TO CURES LIKE THOSE THAT OCCURRED IN THE TWO WOMEN MENTIONED ABOVE. TARGET GRANTS REDUCING THE HIV RESERVOIR DR. JAMES TERMINI, OF THE UNIVERSITY OF MIAMI, IS STUDYING ANTI-HIV BNABS, WHICH CAN CONTROL HIV REPLICATION IN THE ABSENCE OF ANTIRETROVIRALS IN ANIMAL MODELS BUT HAVE NOT BEEN SHOWN TO ERADICATE HIV RESERVOIRS. DR. TERMINI IS INVESTIGATING IF USING SUCH ANTIBODIES WITH GREATLY ENHANCED ABILITY TO PROMOTE A FORM OF ANTI-VIRUS IMMUNITY KNOWN AS ADCC, OR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY, MIGHT OVERCOME THIS ROADBLOCK. DR. MARY ANN CHECKLEY-LUTTGE, OF CASE WESTERN RESERVE UNIVERSITY, IS TESTING TWO TYPES OF GENETICALLY ENGINEERED NATURAL KILLER (NK) CELLS, OR INK CELLS, TO REDUCE THE HIV RESERVOIR. ONE OF THESE CELL TYPES IS GENETICALLY ENGINEERED TO INCLUDE CAR GENES. CAR T CELLS HAVE BEEN HIGHLY EFFECTIVE IN THE TREATMENT OF CERTAIN TYPES OF BLOOD CANCERS. COMBINING THE INK CELLS WITH BNABS, SHE AND HER TEAM WILL ASSESS THEIR POTENCY AGAINST HIV RESERVOIRS IN TEST-TUBE STUDIES. IF THE RESEARCHERS SEE MORE THAN A 50% REDUCTION IN INTACT HIV RESERVOIR VIRUS FROM CELLS TAKEN FROM SIX PEOPLE LIVING WITH HIV, THE TEAM WILL CONSIDER THE NEXT STEPIN VIVO ANIMAL AND HUMAN STUDIES. DR. YIMING YIN, OF BOSTON CHILDREN'S HOSPITAL, AIMS TO GENETICALLY ENGINEER B CELLS, IMBUING THEM WITH THE ABILITY TO TARGET CRITICAL PORTIONS OF THE HIV ENVELOPE. DR. YIN IS TESTING A HYPOTHESIS THAT B CELLS EXPRESSING ANTIBODIES CAPABLE OF NEUTRALIZING DIFFERENT HIV VARIANTS COULD REDUCE THE SIZE OF THE HIV RESERVOIR AND PERHAPS EVEN REPLACE ANTIRETROVIRAL THERAPY. BORROWING FROM CANCER THERAPIES TWO RESEARCHERS WHO RECEIVED TARGET GRANTS ARE STUDYING THE ABILITY OF ANTI-CANCER AGENTS TO TAKE ADVANTAGE OF THE HIV RESERVOIR'S VULNERABILITIES. DR. MICHAEL PELUSO OF UCSF IS TESTING THE IMMUNITY-STIMULATING ABILITY OF A DRUG USED TO TREAT BLADDER CANCER TO SUPPRESS HIV REBOUND IN PEOPLE AFTER TREATMENT INTERRUPTION. AND DR. ADAM SPIVAK, OF THE UNIVERSITY OF UTAH, SALT LAKE CITY, IS INVESTIGATING THE POTENTIAL OF A LEUKEMIA DRUG FOR REDUCING THE HIV RESERVOIR BY EXPLOITING ITS ABILITY TO BLOCK T CELL PROLIFERATION, A FUNDAMENTAL MECHANISM OF HIV PERSISTENCE. MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH IN 2024, AMFAR AWARDED TWO MATHILDE KRIM FELLOWSHIPS IN THE AMOUNT OF $180,000 EACH TO RESEARCHERS ATTEMPTING TO CLOSE CRITICAL KNOWLEDGE GAPS IN HIV CURE RESEARCH. DR. GABRIEL DUETTE, OF THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH IN WESTMEAD, AUSTRALIA, IS STUDYING HOW SOME PEOPLE ARE ABLE TO CONTROL HIV AFTER REPEATED STRATEGIC TREATMENT INTERRUPTIONS BY ANALYZING IF THESE STOP-AND-START CYCLES LEAD TO AN INCREASE OF CD8+ KILLER T CELLS CAPABLE OF CLEARING HIV-INFECTED CELLS FROM THE BODY AND WHETHER THEY CAN INFLUENCE THE GENETIC MAKEUP OF REBOUNDING VIRUS. DR. SIMONE RICHARDSON, OF THE NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES IN JOHANNESBURG, SOUTH AFRICA, IS USING HER AWARD TO STUDY A SEGMENT OF ANTIBODY MOLECULES KNOWN AS FC, WHICH REGULATE ANTI-HIV IMMUNE RESPONSES PRODUCED BY POTENT ANTIBODIES. DR. RICHARDSON'S STUDY COULD CONTRIBUTE TO THE DEVELOPMENT OF BOTH THERAPEUTIC AND PROTECTIVE HIV VACCINES. NAMED IN HONOR OF AMFAR'S LATE FOUNDING CHAIRMAN, THE KRIM FELLOWSHIP HAS PROVIDED CRUCIAL FUNDING FOR OUTSTANDING YOUNG RESEARCHERS SINCE 2008. TO DATE, THE PROGRAM HAS SUPPORTED 62 SCIENTISTS WITH $9.7 MILLION IN FUNDING. THIS CRITICAL INVESTMENT HAS PRODUCED REMARKABLE DIVIDENDS: EVERY DOLLAR SPENT ON THE PROGRAM HAS GENERATED ON AVERAGE $24 IN SUBSEQUENT FUNDING FROM THE NATIONAL INSTITUTES OF HEALTH. AMFAR CURE TRIAL THE RELATIVE SUCCESS OF A GROUNDBREAKING AMFAR-FUNDED CURE TRIAL PROMPTED NEW RESEARCHONE STUDY EXAMINING THE PERSONAL EXPERIENCES AND NEEDS OF PEOPLE LIVING WITH HIV ENROLLED IN CURE-RELATED TRIALS INVOLVING EXTENDED TREATMENT INTERRUPTIONS AND TWO STUDIES FOCUSING ON THE IMMUNITY-RELATED MECHANISMS OF POST-TREATMENT CONTROL OF THE VIRUS. THE LATTER TWO STUDIES WERE PRESENTED AT THE 2024 CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) ALONG WITH ANOTHER STUDY, LED BY DR. TOONG SENG TAN OF THE RAGON INSTITUTE OF MGH, MIT AND HARVARD AND BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON. THE RESEARCHERS, INCLUDING SEVERAL AMFAR GRANTEES, CHARACTERIZED LITTLE-UNDERSTOOD SEX-SPECIFIC DIFFERENCES IN THE HIV RESERVOIR AMONG LONG-TERM ART-TREATED INDIVIDUALS BY LOOKING AT SIGNIFICANT FEATURES OF LATENTLY INFECTED CELLS. THEY NOTED A POTENTIAL SEX-BASED DIFFERENCE IN HOW THE IMMUNE RESPONSES IN TREATMENT-EXPERIENCED PEOPLE DRIVE THE EVOLUTION OF THE HIV RESERVOIRTHE RESERVOIR IN WOMEN WAS SHOWN TO HAVE FEATURES ASSOCIATED WITH DEEPER LATENCY, CELLS THAT ARE LESS SUSCEPTIBLE TO REACTIVATION AND MORE EASILY "LOCKED." PUBLISHED RESEARCH AMFAR IS A LEADING VOICE IN THE SCIENTIFIC CONVERSATION PERTAINING TO HIV, AS EVIDENCED BY THE MANY AMFAR-FUNDED RESEARCH STUDIES PUBLISHED IN PEER-REVIEWED JOURNALS. IN FY2024, 20 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. HIGHLIGHTS INCLUDE: THE "GENEVA PATIENT" STEM CELL TRANSPLANTATION USING DONOR CELLS WITH A CCR5 DELTA32 MUTATION, WHICH RENDERS CELLS NEARLY IMPERVIOUS TO HIV INFECTION, HAS BEEN THE METHOD USED TO CURE HIV IN THE FIRST FIVE CASES. HOWEVER, THE "GENEVA PATIENT," WHOSE SUSTAINED HIV REMISSION WAS CONFIRMED IN 2024, RECEIVED "WILD TYPE" DONOR CELLS, WHICH DO NOT HAVE THE GENETIC MUTATION AND ARE THUS SUSCEPTIBLE TO THE VIRUS. DESCRIBING THE CASE, RESEARCHERS SUGGESTED IT COULD OPEN UP A VERY DIFFERENT AVENUE OF CURE RESEARCH. THEY BELIEVE THAT ALLOGENEIC IMMUNITY, OR A GRAFT-VERSUS-HOST RESPONSEA KEY PART OF CERTAIN CANCER CURES FOLLOWING STEM CELL TRANSPLANTS WITH "NORMAL" DONORSMAY HAVE BEEN INVOLVED AND MIGHT BE REPLICATED WITHOUT REQUIRING A TRANSPLANT. THE STUDY AUTHORS INCLUDE AMFAR GRANTEES DRS. ASIER SEZ-CIRIN (PRINCIPAL INVESTIGATOR), MONIQUE NIJHUIS, ANNEMARIE WENSING, AND JAVIER MARTNEZ PICADO. NEW CASE OF POST-TREATMENT CONTROL A RECENTLY PUBLISHED STUDY DETAILED A NEW CASE OF POST-TREATMENT CONTROL OF HIV. DIAGNOSED IN 1998, THE MAN STARTED ART, SUPPRESSED HIS VIRAL LOAD TO UNDETECTABLE LEVELS SEVEN MONTHS LATER, AND EVENTUALLY DISCONTINUED ALL REGIMENS. EXCEPT FOR ONE SMALL SPIKE SEVEN MONTHS AFTER HE STOPPED ART, HE HAS REMAINED UNDETECTABLE (BELOW 200 COPIES) FOR CLOSE TO TWO DECADES POST-TREATMENT. COMPREHENSIVE ANALYSES BY RESEARCHERS, INCLUDING PAST AMFAR GRANTEE DR. JORI SYMONS OF UNIVERSITY MEDICAL CENTER UTRECHT, THE NETHERLANDS, SUGGEST THAT POST-TREATMENT CONTROL MAY HAVE BEEN THE RESULT OF STRONG CD8 IMMUNE RESPONSES AND A VIRUS THAT SEEMED SLOW TO REPLICATE POSSIBLY DUE TO A MUTATION. TIMING IS IMPORTANT RESEARCHERS AT UCSF ANALYZED HIV DNA IN 500 BLOOD SAMPLES COLLECTED OVER THE COURSE OF A YEAR FROM 67 PEOPLE GIVEN ART DURING ACUTE INFECTION, AND THEN DEVELOPED MATHEMATICAL MODELS PREDICTING THE DECLINE IN HIV RESERVOIRS OVER TIME. PUBLISHED IN MEDRXIV, THE STUDY FOUND THAT TIMING WAS IMPORTANT. IN THE FIRST PHASE OF RESERVOIR DEVELOPMENT, FOR EVERY WEEK ART WAS DELAYED, THE HALF-LIFE OF INTACT HIV INCREASED BY 14 HOURS, BUT FOR EVERY WEEK ART WAS DELAYED IN THE PERIOD 524 WEEKS POST-INFECTION THE VIRUS HALF-LIFE INCREASED BY EIGHT DAYS. THE AUTHORS, INCLUDING AMFAR GRANTEE DR. STEVEN DEEKS, CONCLUDED THAT THEIR STUDY MAY HELP PERSONALIZE CURE STRATEGIES FOR A DIVERSE, GLOBAL POPULATION OF PLWH INITIATING ART AT VARYING STAGES OF HIV. FORM 990, PART III, LINE 4A HOW ONE CURE STRATEGY MAY LEAD TO ANOTHER PUBLISHED IN LANCET HIV AND CO-AUTHORED BY MEMBERS OF THE AMFAR-ESTABLISHED ICISTEM RESEARCH CONSORTIUM, A STUDY SOUGHT TO EXAMINE CHANGES IN HIV RESERVOIRS AND HIV ANTIBODY PRODUCTION OVER MORE THAN EIGHT YEARS OF FOLLOW-UP POST-STEM CELL TRANSPLANT, CURRENTLY THE ONLY STRATEGY THAT HAS SUCCESSFULLY CURED INDIVIDUALS OF HIV. RESEARCHERS AIMED TO DEFINE MECHANISMS CONTRIBUTING TO DECREASES IN HIV RESERVOIR SIZE EVEN IN THOSE WHO RECEIVED A NORMAL DONOR TRANSPLANT (WITHOUT THE CCR5 MUTATION ASSOCIATED WITH A COMPLETE CURE) AND WERE NOT CURED. HIV RESERVOIRS IN THE BLOOD WERE MARKEDLY REDUCED IMMEDIATELY AFTER ACHIEVING FULL REPLACEMENT OF PATIENT CELLS WITH DONOR CELLS POST-TRANSPLANT. THIS OCCURRED REGARDLESS OF WHETHER THE DONOR HAD THE CCR5 MUTATION. THIS DECREASE WAS USUALLY FOLLOWED BY DECREASES IN RESERVOIR HIV IN BONE MARROW, LYMPH NODE, SPINAL FLUID, AND INTESTINES. LEVELS OF ANTI-HIV ANTIBODIES DECLINED MUCH MORE SLOWLY. SO-CALLED "ALLOGENEIC IMMUNITY"DONOR IMMUNE CELL ATTACK ON HIV-INFECTED PATIENT CELLSAPPEARED TO BE THE MAIN MECHANISM FOR REDUCTION IN HIV RESERVOIRS AFTER AN INITIAL MASSIVE DECREASE IN RESERVOIR SIZE RELATED TO THE LARGE DOSES OF CHEMOTHERAPY REQUIRED JUST PRIOR TO THE TRANSPLANT. CREATING A COST-EFFECTIVE CURE A CANADIAN GROUP LED BY AMFAR GRANTEE DR. ERIC ARTS DEVELOPED A NEW TYPE OF LATENCY REVERSING AGENT (LRA) CALLED HLPA DEAD, HIV-LIKE PARTICLE THAT COULD ACTIVATE RESERVOIR T CELLS, THUS MAKING THEM A TARGET. THE CONCEPT WAS EXPLORED USING CELLS FROM INDIVIDUALS ON ART FOR TWO TO THREE YEARS WHO STARTED TREATMENT DURING ACUTE HIV INFECTION, OR SHORTLY THEREAFTER. AS HOPED, IN THE TEST TUBE HLP INDUCED ALMOST 100-FOLD GREATER LATENCY REVERSAL THAN EXISTING AGENTS. WHEN TESTED, HLPS PROVED EQUALLY EFFECTIVE IN INDIVIDUALS WHO HAD STARTED TREATMENT LATER THAN THOSE IN THE INITIAL STUDIES, LEADING TO 100 TO 1,000-FOLD MORE HIV RELEASE THAN PREVIOUS LRAS. THE RESEARCHERS SPECULATED THAT MULTIPLE INJECTIONS OF HLP INTO MUSCLE, LIKE A VACCINATION, COULD ALSO BOOST ANTI-HIV IMMUNE RESPONSES. HLPS THAT COULD RECOGNIZE SUBTYPES OF HIV FOUND PRIMARILY IN THE WEST AS WELL AS IN AFRICA WERE DESIGNED. THE AUTHORS CONCLUDED THAT HLP SERVES AS BOTH AN LRA AS WELL AS TREATMENT THAT CAN BOOST HIV-1-SPECIFIC IMMUNE RESPONSES, SUGGESTING THE POSSIBILITY OF A GLOBAL, COST-EFFECTIVE CURE STRATEGY FOR THE FUTURE. THE STUDY WAS PUBLISHED IN EMERGING MICROBES AND INFECTIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. FORM 990, PART VI, SECTION B, LINE 15 AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED ANNUALLY BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. FORM 990, PART VI, SECTION C, LINE 19 AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. FORM 990, PART XI, LINE 9: OVERACCRUAL OF GRANT EXPENSE -296,424. WRITE OFF OF UNCOLLECTIBLE PLEDGES -499. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.